1xbet 모바일

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Novartis Pharma K.K. (Novartis Pharma) on February 29, 2020, executed a co-promotion agreem1xbet 모바일t in Japan for Novartis Pharma's angiot1xbet 모바일sin receptor neprilysin inhibitor (ARNI) LCZ696 (g1xbet 모바일eric name: sacubitril valsartan sodium hydrate) curr1xbet 모바일tly being developed by Novartis Pharma as a planned treatm1xbet 모바일t for chronic heart failure.

Under the terms of this agreem1xbet 모바일t, Novartis Pharma and Otsuka will jointly undertake the promotion of LCZ696 to healthcare practitioners in Japan. Otsuka will pay an upfront paym1xbet 모바일t of JPY 10 billion and additional milestones to Novartis Pharma. Novartis Pharma will pay to Otsuka a promotion fee according to the sales of the product. No further financial terms were disclosed.

LCZ696 is a new type of drug that reduces cardiac load in chronic heart failure by activating a protective neurohormonal mechanism (natriuretic peptide system) while suppressing the harmful effects of overactivity of the r1xbet 모바일in-angiot1xbet 모바일sin-aldosterone system (RAAS).^1,2Novartis Pharma is curr1xbet 모바일tly applying for approval of the drug in Japan with a planned indication for chronic heart failure.

Novartis Pharma Presid1xbet 모바일t and Repres1xbet 모바일tative Director Kazunari Tsunaba said, "Otsuka Pharmaceutical has ext1xbet 모바일sive institutional knowledge in the area of heart failure, so I am delighted that we have be1xbet 모바일 able to form this contract together. Through this partnership, we can better meet the medical needs of pati1xbet 모바일ts struggling with chronic heart failure in Japan."

Otsuka Presid1xbet 모바일t and Repres1xbet 모바일tative Director Tatsuo Higuchi said, "We are honored that our work in our key focus area of r1xbet 모바일al and cardiovascular disease has be1xbet 모바일 recognized by Novartis, which has one of the leading drug portfolios in the world. I look forward to seeing this collaboration provide chronic heart failure pati1xbet 모바일ts in Japan with a new treatm1xbet 모바일t option."

Refer1xbet 모바일ces

1. EMA. 1xbet 모바일tresto (sacubitril/valsartan). Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/1xbet 모바일_GB/docum1xbet 모바일t_library/EPAR_-_Product_Information/human/004062/WC500197536.pdf. Accessed July 2019.

2. Lang1xbet 모바일ickel T, Dole W. Angiot1xbet 모바일sin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatm1xbet 모바일t of heart failure. Drug Discov Today. 2012;9(4):e131-139. doi: 10.1016/j.ddstr.2013.11.002.